However, more interestingly, it also possessed an acylaminophenoxybenzamide scaffold similar to that of the FDA approved Raf kinase inhibitor sorafenib—a drug which in combination with HDAC inhibitors has shown synergistic effects in cancer treatment [89]. This evidence concerns the gene HDAC9 and cancer.